H.C. Wainwright lowered the firm’s price target on Kymera Therapeutics (KYMR) to $54 from $60 and keeps a Buy rating on the shares. The firm cites the company’s pipeline development programs revised spending assumptions in 2025 and beyond for the target cut.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics: Promising Developments and Strategic Positioning Make It a Compelling Buy
- Kymera Therapeutics Reports 2024 Financial Results and Pipeline Progress
- Kymera Therapeutics reports Q4 EPS (88c), consensus (79c)
- Is KYMR a Buy, Before Earnings?
- Kymera Therapeutics Unveils 2025 Strategy and Trials